A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of A Topical Unani Formulation In The Management Of Qub ? (Tinea Corporis) - NA

ational Research Institute Of Unani Medicine For Skin Disorders0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1 Participants of any gender in age group of 18-60 years
•2 Participants of Qub ?(Tinea Corporis) having circumscribed lesions with any of the following signs and symptoms on body and limbs:
•a Presence of pruritus and burning
•b Presence of scales
•c Presence of central clearing
•d Erythematous papules
•3 Participants with Positive KOH (10%) Smear Microscopy of Skin Scrapping from the active lesion for Dermatophytic hyphae
•Participants who are willing to participate and comply with the protocol and sign to IEC approved ICF.

•The following patients will be excluded:
•Age below 18 years and above 60 years
•Patients with other form of tinea infection like tinea cruris (groin), tinea capitis (head), tinea pedis (foot), tinea mannum (hands), tinea unguium (nails), tinea barbae (beard), tinea faciei (face),etc.
•Patient with other concomitant diseases like psoriasis & eczema
•Patients who have received any topical antifungal therapy within last 2 weeks or oral antifungal therapy in the previous 4 weeks
•Patients with known active pulmonary/ cardiovascular/ liver/ renal or neurological diseases
•Known cases of Diabetes Mellitus or other immunocompromised disorders (HIV/ AIDS, etc.)/ Malignancies
•Patients with long-term history of steroid, cytotoxic and immunosuppressive therapy
•History of hypersensitivity to either itraconazole or any test drug
•Pregnant or lactating women, and women desiring pregnancy
•Participants not willing to give consent and to attend treatment schedule regularly

发起方

ational Research Institute Of Unani Medicine For Skin Disorders